Bortezomib in the second-line treatment of plasma cell myeloma when thalidomide treatment fails

Abstract

Plasma cell myeloma (PCM) constitutes 10% of all diagnosed haematological malignancies. Whenever indicated, such patients aged below 65 years receive a regimen of cytotoxic treatment along with autologous hematopoietic stem cell transplantation (auto-HSCT). Using a case study example of a 62 year old man, this article describes a standard regimen for treating patients in Poland from this age group, who qualify for the auto-HSCT.